Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 12 February 2019
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc (the 'Company')
 
Conditional Share Awards and Shares withheld or sold to meet tax liabilities
 
This notification sets out the details of the vesting of awards and the sale or withholding of shares to meet tax liabilities over Ordinary Shares made in 2016 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group. The restricted period for the 2016 SVP awards has now ended and the awards made to Persons Discharging Managerial Responsibility (PDMRs) vested on 11 February 2019.
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position / status
SVP & General Counsel
c)
Initial notification / amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
n/a
6,320
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position / status
SVP & General Counsel
c)
Initial notification / amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.2654
3,113
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position / status
CEO, GSK Consumer Healthcare
c)
Initial notification / amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
n/a
11,212
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position / status
CEO, GSK Consumer Healthcare
c)
Initial notification / amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.2654
5,522
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharma Supply Chain
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
n/a
11,060
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
London Stock Exchange (XLON)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharma Supply Chain
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.5380
5,199
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
London Stock Exchange (XLON)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
   
b)
Nature of the transaction
The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
n/a
11,060
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
London Stock Exchange (XLON)
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.5380
5,199
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
 
e)
Date of the transaction
2019-02-11
f)
Place of the transaction
London Stock Exchange (XLON)
  
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 12, 2019 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc